我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

中国急性冠脉综合征患者高强度他汀治疗的安全性meta分析

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2018年第2期
页码:
154-158
栏目:
临床研究
出版日期:
2018-02-15

文章信息/Info

Title:
Safety of intensive statins therapy inChinese patients with acute coronary syndrome: a meta-analysis
作者:
王文晓1; 2; 杨 贤1; 方 芸1
（1.南京大学医学院附属鼓楼医院药学部，江苏 南京 210008；2.中国药科大学基础医学与临床药学学院，江苏 南京 210009）
Author(s):
WANG Wen-xiao1; 2;  YANG Xian1;  FANG Yun1
(1.Department of Pharmacy, Gulou Hospital, Affiliated to Medical College of Nanjing University, Nanjing 210008, Jiangsu, China; 2.College of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, Jiangsu, China)
关键词:
高强度他汀; 中国人群; 急性冠脉综合征; 安全性; meta分析
Keywords:
intensive statins;  Chinese patients;  acute coronary syndrome;  safety;  meta-analysis
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 用meta分析评价中国急性冠脉综合征患者启动高强度他汀治疗的安全性。方法 收集关于中国急性冠脉综合征患者早期高强度他汀治疗的随机对照临床试验（RCT），按照纳入与排除标准筛选文献，评价文献质量并提取有效数据，采用RavMan5.3进行meta分析。结果 共纳入相关研究19篇，包括2 749例患者。Meta分析结果显示:高强度他汀明显增加肌肉不良反应［OR=2.3,95%CI(1.24,4.28),P<0.01］和肝脏损伤［OR=2.10,95%CI(1.36,3.24),P<0.01］，不增加肾脏损害［OR=0.67,95%CI(0.19,2.38),P=0.53］和消化道症状［OR=1.05,95%CI(0.58,1.93),P=0.72］。 结论 中国急性冠脉综合征患者使用高强度他汀治疗的安全性较常规剂量他汀低。
Abstract:
AIM To review the safety of intensive statins therapy in Chinese patients with acute coronary syndrome. METHODS Randomized controlled clinical trials (RCT) related to intensive statin therapy in Chinese patients with acute coronary syndrome were collected and selected according to inclusion and to exclusion criteria. The methodological quality of the included RCTs was assessed and data analyses were performed with Cochrane Collaboration’s RevMan 5.3. RESULTS In the present investigation, 19 trials, including 2749 patients were selected. Meta analysis showed that intensive statins increased statin-associated muscle symptoms［OR=2.3, 95%CI(1.24, 4.28), P<0.01］ and damage liver［OR=2.10, 95%CI(1.36, 3.24), P<0.01］, without increasing kidney damage［OR=0.67, 95%CI(0.19, 2.38), P=0.53］ and gastrointestinal symptoms［OR=1.05, 95%CI(0.58, 1.93), P=0.72］. CONCLUSION The safety of intensive statins therapy in Chinese patients with acute coronary syndrome is lower than regular statins therapy.

参考文献/References

[1]The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology(ESC)and European Atherosclerosis Society(EAS).2016 ESC/EAS Guidelines for the Management of Dyslipidaemias[J].Eur Heart J,2016,74(11):1234-1318.

[2]Stone NJ,Robinson JG,Lichtenstein AH,et al.2013 ACC/AHA guideline on the treatment of blood cholesterol toreduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].Am Coll Cardiol,2014,63(25 Pt B):3024-3025.

[3]霍 勇,葛均波,韩雅玲,等.2014急性冠状动脉综合征患者强化他汀治疗专家共识[J].中国介入心脏病学杂志,2014,22(1):4-6.

[4]Tang X,Yang Y,Luo S,et al.The effect of statin therapy on plaque regression following acute coronary syndrome: a meta-analysis of prospective trials[J].Coron Artery Dis,2016,27(8):636-649.

[5]HPS2-THRIVE Collaborative Group.HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant:trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment[J].Eur Heart J,34(17):1279-1291.

[6]周 颖,姜 红,王 勇.强化他汀治疗的种族差异-中国人适合强化他汀治疗吗?[J].医学综述,2012,18(4):591-593.

[7]樊维娜,王建新,孙经武.不同剂量阿托伐他汀钙在亚洲人急性心肌梗死治疗中应用疗效观察[J].陕西医学杂志,2016,45(1):93-95.

[8]常快乐,魏敦宏,付清海.强化他汀治疗冠状动脉慢血流的临床观察[J].宁夏医科大学学报,2015,37(4):433-435.

[9]陈 晖,马 蕾,余淑华.强化他汀治疗对经皮冠状动脉介入治疗的心脏保护研究[J].中国临床医生杂志,2015,43(7):39-41.

[10]陈少源,方红城,金 键,等.强化他汀治疗对ACS患者血清IL-37的影响[J].中国循证心血管医学杂志,2014,6(4):404-407.

[11]陈铁汉,孙黎明,王怡练,等.PCI术后短期内应用强化他汀治疗对患者出血风险的临床研究[J].实用药物与临床,2016,19(1):120-122.

[12]关贤颂.强化他汀治疗对急性冠脉综合征患者PCI术后心肌灌注及炎症因子的影响[J].中国医药导报,2012,9(16):97-98.

[13]李 芳,王晓华,张鹏宇,等.不同剂量阿托伐他汀对≥85岁急性冠脉综合征患者疗效和安全性研究[J].实用老年医学,2014,28(6):493-496.

[14]李京倡,张 晓.早期阿托伐他汀强化治疗对急性冠脉综合征患者PCI术后预后的影响[J].中国现代医学杂志,2012,22(31):61-64.

[15]廖育山,洪长江,李志雄.高剂量与低剂量瑞舒伐他汀对急性冠脉综合征患者血清脑钠肽、炎性因子及血脂水平的影响观察[J].临床与病理杂志,2016,36(9):1393-1398.

[16]邱雪梅,张海英,郭志娟,等.不同剂量阿托伐他汀对急性心肌梗死患者预后及炎症指标的影响[J].中国医刊,2016,51(3):100-102.

[17]王东伟,刘 敏.大剂量瑞舒伐他汀对冠脉支架植入患者血脂、hs-CRP水平及急性冠脉事件发生的影响[J].郑州大学学报(医学版),2012,47(1):72-74.

[18]王亚利,胡申江,王 欢,等.不同剂量瑞舒伐他汀对急性冠脉综合征患者血清高敏C反应蛋白和基质金属蛋白酶-9 的影响[J].中华危重症医学杂志(电子版),2014,7(3):195-197.

[19]肖孟生,符丽珍,朱德康.大剂量阿托伐他汀序贯治疗对急性心肌梗死患者预后的影响及安全性分析[J].河北医药,2017,39(1):124-126.

[20]徐桂华,夏 辉.不同剂量阿托伐他汀治疗急性冠脉综合征临床疗效对比分析[J].安徽医学, 2012,33(8):1016-1018.

[21]许 敏,郭金成,王国忠,等.急诊冠状动脉介入术强化阿托伐他汀治疗的临床疗效[J].临床心血管病杂志,2013,29(1):17-20.

[22]许晓伟,刘亚丽,苏维芳,等.不同剂量瑞舒伐他汀对老年急性冠脉综合征患者血管内皮功能及血脂水平的影响[J].海南医学,2016,27(16):2586-2588.

[23]周 波,付 菱,李 钰.不同剂量阿托伐他汀对不稳定心绞痛患者血脂及血清淀粉样蛋白A、C反应蛋白的影响[J].海南医学,2012,23(4):7-10.

[24]朱立新,华红霞.大剂量瑞舒伐他汀对急性冠状动脉综合征疗效及安全性评估[J].实用临床医药杂志,2014,18(17):105-106.

[25]Zhang B,Jiang J,Liu HL,et al.Efficacy and safety of serial atorvastatin load in Chinese patients undergoing elective percutaneous coronary intervention:results of the ISCAP (Intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) randomized controlled trial[J].Eur Heart J,2015,17(Supplement B),B47-B56.

[26]Cannon CP,Braunwald E,McCabe CH,et al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J].N Engl J Med,2004,350(15):1495-1504.

[27]Bruckert E,Hayem G,Dejager S,et al.Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study[J].Cardiovasc Drugs Ther,2005,19(6):403-414.

[28]Birmingham BK,Bujac SR,Elsby R,et al.Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States[J].Eur J Clin Pharmacol,2015,71(3):329-340.

[29]Dai W,Huang XS,Zhao SP.No evidence to support high-intensity statin in Chinese patients with coronary heart disease[J].Int J Cardiol,2016,1(204):57-58.

备注/Memo

备注/Memo:
收稿日期：2017-04-16.通讯作者：方芸，主任药师，主要从事临床药学研究 Email:njglfy@163.com 作者简介：王文晓，硕士生 Email：Moshengren829@126.com
更新日期/Last Update: 1900-01-01